Literature DB >> 11178697

Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization: comparison of Lipiodol-CT, power Doppler sonography, and dynamic MRI.

K Kubota1, N Hisa, T Nishikawa, Y Fujiwara, Y Murata, S Itoh, D Yoshida, S Yoshida.   

Abstract

BACKGROUND: The purpose of this study was to compare the ability of Lipiodol-computed tomography (CT), power Doppler (PD) sonography, and dynamic magnetic resonance imaging (MRI) in evaluating the therapeutic effect of transcatheter arterial chemoembolization (TACE) on hepatocellular carcinoma (HCC).
METHODS: TACE was performed by injecting an emulsion consisting of Lipiodol and a chemotherapeutic drug, followed by gelatin sponge particles, into 54 patients with 84 HCC lesions. Five to 7 days later, Lipiodol-CT, PD sonography, and dynamic MRI were performed. Findings from the three modalities were correlated with relapse within 1 year after TACE.
RESULTS: All lesions with blood flow on PD sonography or intratumoral enhancement on dynamic MRI relapsed regardless of the findings with Lipiodol-CT. None of the negatively enhanced lesions on dynamic MRI relapsed regardless of the Lipiodol-CT findings. However, the readers could not evaluate the contrast uptake in 14 lesions that were already hyperintense on the precontrast images. These cases were considered unsuitable for qualitative assessment and reduced the applicability of MRI to 83% of the examined lesions (70 of 84). Although PD sonography perfectly predicted relapse in superficial (0-5 cm from abdominal surface) lesions of the right hepatic lobe, blood flow in deep (>5 cm) or left lobe lesions was undetectable regardless of the occurrence of relapse. As a result, Lipiodol-CT displayed 76.0% sensitivity, 67.6% specificity, and 72.6% accuracy. The sensitivity, specificity, and accuracy of PD sonography were 34.0%, 100%, and 60.7%, respectively. In the 70 lesions in which evaluation was possible, dynamic MRI achieved 100% sensitivity, 100% specificity, and 100% accuracy.
CONCLUSION: Of the three modalities, dynamic MRI was the best for evaluating the efficacy of TACE in the treatment of HCC. We also found that superficial lesions of the right lobe are good candidates for PD sonography. However, high signals on precontrast MR images, motion artifacts, and ultrasonic attenuation remain key limitations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11178697     DOI: 10.1007/s002610000139

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  28 in total

1.  Multidetector CT in evaluating blood supply of hepatocellular carcinoma after transcatheter arterial chemoembolization.

Authors:  Yong-Song Guan; Xiao-Hua Zheng; Xiang-Ping Zhou; Juan Huang; Long Sun; Xian Chen; Xiao Li; Qing He
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

Review 2.  Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china.

Authors:  Peipei Song; Jianjun Gao; Yoshinori Inagaki; Norihiro Kokudo; Kiyoshi Hasegawa; Yasuhiko Sugawara; Wei Tang
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

3.  Embolization of liver tumors: Past, present and future.

Authors:  Ashwin Rammohan; Jeswanth Sathyanesan; Sukumar Ramaswami; Anand Lakshmanan; Perumal Senthil-Kumar; Ulagendra Perumal Srinivasan; Ravi Ramasamy; Palaniappan Ravichandran
Journal:  World J Radiol       Date:  2012-09-28

4.  Large-sized hepatocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT).

Authors:  Stephan Zangos; Katrin Eichler; Jörn O Balzer; Ralf Straub; Renate Hammerstingl; Christopher Herzog; Thomas Lehnert; Mathias Heller; Axel Thalhammer; Martin G Mack; Thomas J Vogl
Journal:  Eur Radiol       Date:  2006-08-08       Impact factor: 5.315

Review 5.  Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma.

Authors:  Francesco Tovoli; Giulia Negrini; Luigi Bolondi
Journal:  Hepat Oncol       Date:  2016-03-23

6.  Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma.

Authors:  Olivio F Donati; Richard Kinh Gian Do; Andreas M Hötker; Seth S Katz; Junting Zheng; Chaya S Moskowitz; Christopher Beattie; Karen T Brown
Journal:  Eur Radiol       Date:  2015-04-08       Impact factor: 5.315

Review 7.  Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.

Authors:  Ania Kielar; Kathryn J Fowler; Sara Lewis; Vahid Yaghmai; Frank H Miller; Hooman Yarmohammadi; Charles Kim; Victoria Chernyak; Takeshi Yokoo; Jeffrey Meyer; Isabel Newton; Richard K Do
Journal:  Abdom Radiol (NY)       Date:  2018-01

8.  An implantable rat liver tumor model for experimental transarterial chemoembolization therapy and its imaging features.

Authors:  Xin Li; Chuan-Sheng Zheng; Gan-Sheng Feng; Chen-Kai Zhuo; Jun-Gong Zhao; Xi Liu
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

9.  Role and limitation of FMPSPGR dynamic contrast scanning in the follow-up of patients with hepatocellular carcinoma treated by TACE.

Authors:  Fu-Hua Yan; Kang-Rong Zhou; Jie-Min Cheng; Jian-Hua Wang; Zhi-Ping Yan; Reng-Rong Da; Jia Fan; Yuan Ji
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

10.  Changes of tumor microcirculation after transcatheter arterial chemoembolization: first pass perfusion MR imaging and Chinese ink casting in a rabbit model.

Authors:  Jun-Gong Zhao; Gan-Sheng Feng; Xiang-Quan Kong; Xin Li; Ming-Hua Li; Ying-Sheng Cheng
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.